首页> 外国专利> Pharmaceutical composition for preventing or treating obesity or metabolic disorders comprising Aster glehni extract as an active ingredient

Pharmaceutical composition for preventing or treating obesity or metabolic disorders comprising Aster glehni extract as an active ingredient

机译：用于预防或治疗肥胖或代谢异常的药物组合物，其包含紫苑提取物作为活性成分

页面导航

摘要
著录项
相似文献

摘要

The present invention relates to a pharmaceutical composition for preventing or treating obesity or metabolic diseases containing an extract of Aster glehni or a fraction thereof as an active ingredient and a health functional food for preventing or ameliorating obesity or metabolic diseases, The extract according to the present invention or a fraction thereof is effective for reducing body weight, reducing body fat content, reducing plasma glucose and total cholesterol level, decreasing fat accumulation in the body (liver and visceral fat tissue) And by reducing gene expression involved in adipocyte formation, it can be very useful for prevention or treatment of obesity or metabolic diseases.

机译：本发明涉及用于预防或治疗肥胖或代谢性疾病的药物组合物，其含有 Aster glehni 的提取物或其一部分作为有效成分以及用于预防或改善肥胖或代谢性疾病的健康功能性食品。，根据本发明的提取物或其一部分可有效减轻体重，减少体内脂肪含量，降低血浆葡萄糖和总胆固醇水平，减少体内脂肪（肝脏和内脏脂肪组织）的积累并通过减少基因表达由于参与脂肪细胞的形成，它对于预防或治疗肥胖或代谢性疾病非常有用。 展开▼

著录项

公开/公告号KR101523820B1

专利类型

公开/公告日2015-05-28

原文格式PDF

申请/专利权人 상지대학교산학협력단;
展开▼

申请/专利号KR20120111299

发明设计人 안효진;박희준;이헌명;
展开▼

申请日2012-10-08

分类号A61K36/28;A61P3;A61P3/04;

国家 KR

入库时间 2022-08-21 14:58:11

相似文献

专利

外文文献

中文文献

1. 包含抑制二肽基肽酶-IV活性的化合物以及其他抗糖尿病剂或抗肥胖剂作为活性成分的、用于预防和治疗糖尿病或肥胖症的药物组合物 [P] . 中国专利： CN102256605B . 2014.05.07

2. 包含抑制二肽基肽酶-IV活性的化合物以及其他抗糖尿病剂或抗肥胖剂作为活性成分的、用于预防和治疗糖尿病或肥胖症的药物组合物 [P] . 中国专利： CN102256605A . 2011-11-23

3. PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING OBESITY OR METABOLIC DISORDERS COMPRISING ASTER GLEHNI EXTRACT AS AN ACTIVE INGREDIENT [P] . 韩国专利： KR20140045134A . 2014-04-16

机译：预防或治疗肥胖症或代谢紊乱的药物组合物，其中包括ASTER GLEHNI提取物作为有效成分

4. PHARMACEUTICAL COMPOSITION CONTAINING ASTER GLEHNI EXTRACT AS ACTIVE INGREDIENTFOR PREVENTING OR TREATING OBESITY OR METABOLIC DISEASES [P] . 世界知识产权组织专利： WO2014058142A1 . 2014-04-17

机译：含有菊酯提取物作为预防或治疗肥胖或代谢性疾病的有效成分的药物组合物

5. PHARMACEUTICAL COMPOSITION COMPRISING EXTRACT OF ERIOBOTRYA JAPONICA LEAVES AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING OBESITY, HYPERLIPIDEMIA, ATHEROSCLEROSIS, FATTY LIVER, DIABETES MELLITUS, OR METABOLIC SYNDROME [P] . 韩国专利： KR20150142837A . 2015-12-23

机译：包含日本鸢尾叶提取物的药物成分，可作为预防或治疗肥胖，高脂血症，动脉粥样硬化，脂肪肝，糖尿病或代谢综合征的有效成分

1. Simultaneous and Trace Level Quantification of Five Potential Genotoxic Impurities in Ranolazine Active Pharmaceutical Ingredient Using LC-MS/MS [J] . Kartheek Srinivas Chidella, Vijaya Bharathi Dasari, Jayashree Anireddy 美国分析化学（英文） . 2021,第001期

2. Development of a rapid GC-FID method to simultaneously determine triethylamine,diisopropylamine,and 1,1,3,3-tetramethylguanidine residues in an active pharmaceutical ingredient [J] . Minshan Shou, Haixiao Qiu 药物分析学报（英文） . 2021,第002期

3. Multiple Emulsions Able to Be Used for Oral Administration of Active Pharmaceutical Ingredients: Physico-Chemical Parameters Study of Different Phases [J] . Louis Augustin Diaga Diouf, Alphonse Rodrigue Djiboune, Mamadou Soumboundou, 现代物理（英文） . 2020,第010期

4. COMPOSITION COMPRISING AN EXTRACT OF HARDY KIWI FOR PREVENTING OR TREATING BALDNESS DISORDERS OR SEBORRHEIC SKIN DISORDERS [J] . Soap Perfumery and Cosmetics group Soap, Perfumery and Cosmetics . 2014,第12期

5. Patent Issued for Composition Comprising an Extract of Hardy Kiwi for Preventing Or Treating Baldness Disorders Or Seborrheic Skin Disorders [J] . Journal of Engineering . 2013,第13期

6. Treatability Study of Wasterwater Generated at Manufacturing Unit of Pharmaceutical Intermediates and Active Pharmaceutical Ingredients [J] . Arti D. Galgale, Nirav G. Shah, Devki R. Parikh Indian Journal of Environmental Protection . 2013,第3期

7. Normal and Obese Liver Expressional QTLs Reveal Genes and Pathways Underlying Metabolic Disorders [C] . Hao Ke 5th International Conference on Bioinformatics and Biomedical Engineering . 2011

8. Effect of Compression Force on Agglomeration of Micronized Active Pharmaceutical Ingredients: Techniques to Prevent API Agglomeration during Compression. [D] . Potharaju, Suresh. 2012

9. Study on Ajuga reptans Extract: A Natural Antioxidant in Microencapsulated Powder Form as an Active Ingredient for Nutraceutical or Pharmaceutical Purposes [O] . Tiziana Esposito, Francesca Sansone, Giulia Auriemma, 2020

10. Poster session 2Morphogenetic mechanisms290MiR-133 regulates retinoic acid pathway during early cardiac chamber specification291Bmp2 regulates atrial differentiation through miR-130 during early heart looping formationDevelopmental genetics294Association of deletion allele of insertion/deletion polymorphism in alpha 2B adrenoceptor gene and hypertension with or without type 2 diabetes mellitus295Association of G1359A polymorphism of the endocannabinoid type 1 receptor (CNR1) with coronary artery disease (CAD) with type 2 diabetes mellitusCell growth, differentiation and stem cells - Vascular298Gamma-secretase inhibitor prevents proliferation and migration of ductus arteriosus smooth muscle cells: a role of Notch signaling in postnatal closure of ductus arteriosus299Mesenchymal stromal-like cells (MLCs) derived from induced pluripotent stem (iPS) cells: a promising therapeutic option to promote neovascularization300Sonic Hedgehog promotes mesenchymal stem cell differentiation to vascular smooth muscle cells in cardiovacsular disease301Proinflammatory cytokine secretion and epigenetic modification in endothelial cells treated LPS-GinfivalisCell death and apoptosis - Vascular304Mitophagy acts as a safeguard mechanism against human vascular smooth muscle cell apoptosis induced by atherogenic lipidsTranscriptional control and RNA species - Vascular307MicroRNA-34a role in vascular calcification308Local delivery of a miR-146a inhibitor utilizing a clinically applicable approach attenuates neointima formation after vascular injury309Long noncoding RNA landscape of hypoxic endothelial cells310Specific circulating microRNAs levels associate with hypertension, hyperglycemia and dysfunctional HDL in acute coronary syndrome patientsCytokines and cellular inflammation - Vascular313Phosphodiesterase5A up-regulation in vascular endothelium under pro-inflammatory conditions: a newly disclosed anti-inflammatory activity for the omega-3polyunsaturated aatty acid docosahexaenoic acid314Cardiovascular risk modifying with extra-low dose anticytokine drugs in rhematoid arthritis315Conversion of human M-CSF macrophages into foam cells reduces their proinflammatory responses to classical M1-polarizing activation316Lymphocytic myocarditis coincides with increased plaque inflammation and plaque hemorrhage in coronary arteries, facilitating myocardial infarction317Serum osteoprotegerin level predictsdeclined numerous of circulating endothelial- derived and mononuclear-derived progenitor cells in patients with metabolic syndromeGrowth factors and neurohormones - Vascular320Effect of gastrin-releasing peptide (GRP) on vascular inflammationSignal transduction - Heart323A new synthetic peptide regulates hypertrophy in vitro through means of the inhibition of nfkb324Inducible fibroblast-specific knockout of p38 alpha map kinase is cardioprotective in a mouse model of isoproterenol-induced cardiac hypertrophy325Regulation of beta-adrenoceptor-evoked inotropic responses by inhibitory G protein, adenylyl cyclase isoforms 5 and 6 and phosphodiesterases326Binding to RGS3 and stimulation of M2 muscarinic acetylcholine receptors modulates the substrate specificity of p190RhoGAP in cardiac myocytes327Cardiac regulation of post-translational modifications, parylation and deacetylation in LMNA dilated cardiomyopathy mouse model328Beta-adrenergic regulation of the b56delta/pp2a holoenzyme in cardiac myocytes through b56delta phosphorylation at serine 573Nitric oxide and reactive oxygen species - Vascular331Oxidative stress-induced miR-200c disrupts the regulatory loop among SIRT1, FOXO1 and eNOS332Antioxidant therapy prevents oxidative stress-induced endothelial dysfunction and Enhances Wound Healing333Morphological and biochemical characterization of red blood cell in coronary artery diseaseCytoskeleton and mechanotransduction - Heart336Novel myosin activator, JSH compounds, increased myocardial contractility without chronotropic effect in ratsExtracellular matrix and fibrosis - Vascular339Ablation of Toll-like receptor 9 causes cardiac rupture after myocardial infarction by attenuating proliferation and differentiation of cardiac fibroblasts340Altered vascular remodeling in the mouse hind limb ischemia model in Factor VII activating protease (FSAP) deficiencyVasculogenesis, angiogenesis and arteriogenesis343Pro-angiogenic effects of proly-hydroxylase inhibitors and their potential for use in a novel strategy of therapeutic angiogenesis for coronary total occlusion344Nrf2 drives angiogenesis in transcription-independent manner: new function of the master regulator of oxidative stress response345Angiogenic gene therapy, despite efficient vascular growth, is not able to improve muscle function in normoxic or chronically ischemic rabbit hindlimbs -role of capillary arterialization and shunting346Effect of PAR-1 inhibition on collateral vessel growth in the murine hind limb model347Quaking is a key regulator of endothelial cell differentiation, neovascularization and angiogenesis348"Emerging angiogenesis" in the chick chorioallantoic membrane (CAM). An in vivo study349Exosomes from cardiomyocyte progenitor cells and mesenchymal stem cells stimulate angiogenesis in vitro and in vivo via EMMPRINEndothelium352Reciprocal regulation of GRK2 and bradykinin receptor stimulation modulate Ca2+ intracellular level in endothelial cells353The roles of bone morphogenetic proteins 9 and 10 in endothelial inflammation and atherosclerosis354The contribution of GPR55 to the L-alpha-lysophosphatidylinositol-induced vasorelaxation in isolated human pulmonary arteries355The endothelial protective ACE inhibitor Zofenoprilat exerts anti-inflammatory activities through H2S production356A new class of glycomimetic drugs to prevent free fatty acid-induced endothelial dysfunction357Endothelial progenitor cells to apoptotic endothelial cell-derived microparticles ration differentiatesas preserved from reduced ejection fractionheart failure358Proosteogenic genes are activated in endothelial cells of patients with thoracic aortic aneurysm359Endothelin ETB receptors mediate relaxing responses to insulin in pericardial resistance arteries from patients with cardiovascular disease (CVD)Smooth muscle and pericytes362CX3CR1 positive myeloid cells regulate vascular smooth muscle tone by inducing calcium oscillations via activation of IP3 receptors363A novel function of PI3Kg on cAMP regulation, role in arterial wall hyperplasia through modulation of smooth muscle cells proliferation364NRP1 and NRP2 play important roles in the development of neointimal hyperplasia in vivo365Azithromycin induces autophagy in aortic smooth muscle cellsCoagulation, thrombosis and platelets368The real time in vivo evaluation of platelet-dependent aldosterone prothrombotic action in mice369Development of a method for in vivo detection of active thrombi in mice370The antiplatelet effects of structural analogs of the taurine chloramine371The influence of heparin anticoagulant drugs on functional state of human platelets372Regulation of platelet aggregation and adenosine diphosphate release by d dimer in acute coronary syndrome (in vitro study)Oxygen sensing, ischaemia and reperfusion375Sirtuin 5 mediates brain injury in a mouse model of cerebral ischemia-reperfusion376Abscisic acid: a new player in cardiomyocyte protection from ischaemia?377Protective effects of ultramicronized palmitoylethanolamide (PEA-um) in myocardial ischaemia and reperfusion injury in vivo378Identification of stem cell-derived cardiomyocytes using cardiac specific markers and additional testing of these cells in simulated ischemia/reperfusion system379Single-dose intravenous metformin treatment could afford significant protection of the injured rat kidney in an experimental model of ischemia-reperfusion380Cardiotoxicity of long acting muscarinic receptor antagonists used for chronic obstructive pulmonary disease381Dependence antioxidant potential on the concentration of amino acids382The impact of ischemia-reperfusion on physiological parameters,apoptosis and ultrastructure of rabbit myocardium with experimental aterosclerosisMitochondria and energetics385MicroRNA-1 dependent regulation of mitochondrial calcium uniporter (MCU) in normal and hypertrophied hearts386Mitochondrial homeostasis and cardioprotection: common targets for desmin and aB-crystallin387Overexpression of mitofusin-2 (Mfn2) and associated mitochondrial dysfunction in the diabetic heart388NO-dependent prevention of permeability transition pore (MPTP) opening by H2S and its regulation of Ca2+ accumulation in rat heart mitochondria389G protein coupled receptor kinase 2 (GRK2) is fundamental in recovering mitochondrial morphology and function after exposure to ionizing radiation (IR)Gender issues392Sex differences in pulmonary vascular control; focus on the nitric oxide pathwayAging395Heart failure with preserved ejection fraction develops when feeding western diet to senescence-accelerated mice396Cardiovascular markers as predictors of cognitive decline in elderly hypertensive patients397Changes in connexin43 in old rats with volume overload chronic heart failureGenetics and epigenetics400Calcium content in the aortic valve is associated with 1G>2G matrix metalloproteinase 1 polymorphism401Neuropeptide receptor gene s (NPSR1) polymorphism and sleep disturbances402Endothelin-1 gene Lys198Asn polymorphism in men with essential hypertension complicated and uncomplicated with chronic heart failure403Association of common polymorphisms of the lipoprotein lipase and pon1 genes with the metabolic syndrome in a sample of community participantsGenomics, proteomics, metabolomics, lipidomics and glycomics405Gene expression quantification using multiplexed color-coded probe pairs to determine RNA content in sporadic cardiac myxoma406Large-scale phosphorylation study of the type 2 diabetic heart subjected to ischemia / reperfusion injury407Transcriptome-based identification of new anti-inflammatory properties of the olive oil hydroxytyrosol in vascular endothelial cell under basal and proinflammatory conditions408Gene polymorphisms combinations and risk of myocardial infarctionComputer modelling, bioinformatics and big data411Comparison of the repolarization reserve in three state-of-the-art models of the human ventricular action potentialMetabolism, diabetes mellitus and obesity414Endothelial monocyte-activating polypeptide-II improves heart function in type -I Diabetes mellitus415Admission glucose level is independent predictor of impaired left ventricular function in patients with acute myocardial infarction: a two dimensional speckle-tracking echocardiography study416Association between biochemical markers of lipid profile and inflammatory reaction and stiffness of the vascular wall in hypertensive patients with abdominal obesity417Multiple common co-morbidities produce left ventricular diastolic dysfunction associated with coronary microvascular dysfunction, oxidative stress and myocardial stiffening418Investigating the cardiovascular effects of antiretroviral drugs in a lean and high fat/sucrose diet rat model of obesity419Statins in the treatment of non-alcoholic steatohepatitis (NASH). Our experience from a 2-year prospective study in Constanta County, Romania420Epicardial adipose tissue as a predictor of cardiovascular outcome in patients with ACS undergoing PCI?Arterial and pulmonary hypertension423Dependence between heart rhythm disorers and ID polymorphism of ACE gene in hypertensive patients424Molecular mechanisms underlying the beneficial effects of Urocortin 2 in pulmonary arterial hypertension425Inhibition of TGf-b axis and action of renin-angiotensin system in human ascending aorta aneurysms426Early signs of microcirculation and macrocirculation abnormalities in prehypertension427Vascular smooth muscle cell-expressed Tie-2 controls vascular tone428Cardiac and vascular remodelling in the development of chronic thrombo-embolic pulmonary hypertension in a novel swine modelBiomarkers431Arrhythmogenic cardiomyopathy: a new, non invasive biomarker432Can circulating microRNAs distinguish type 1 and type 2 myocardial infarction?433Design of a high-throughput multiplex proteomics assay to identify left ventricular diastolic dysfunction in diabetes434Monocyte-derived and P-selectin-carrying microparticles are differently modified by a low fat diet in patients with cardiovascular risk factors who will and who will not develop a cardiovascular event435Red blood cell distribution width assessment by polychromatic interference microscopy of thin films in chronic heart failure436Invasive and noninvasive evaluation of quality of radiofrequency-induced cardiac denervation in patients with atrial fibrillation437The effect of therapeutic hypothermia on the level of brain derived neurotrophic factor (BDNF) in sera following cardiopulmonary resustitation438Novel biomarkers to predict outcome in patients with heart failure and severe aortic stenosis439Biological factors linking depression and anxiety to cardiovascular disease440Troponins and myoglobin dynamic at coronary arteries graftingInvasive, non-invasive and molecular imaging443Diet composition effects on the genetic typing of the mouse ob mutation: a micro-ultrasound characterization of cardiac function, macro and micro circulation and liver steatosis444Characterization of pig coronary and rabbit aortic lesions using IV-OCT quantitative analysis: correlations with histologyGene therapy and cell therapy447Enhancing the survival and angiogenic potential of mouse atrial mesenchymal cells448VCAM-1 expression in experimental myocardial infarction and its relation to bone marrow-derived mononuclear cell retentionTissue engineering451Advanced multi layered scaffold that increases the maturity of stem cell-derived human cardiomyocytes452Response of engineered heart tissue to simulated ischemia/reperfusion in the presence of acute hyperglycemic conditions453Serum albumin hydrogels prevent de-differentiation of neonatal cardiomyocytes454A novel paintbrush technique for transfer of low viscosity ultraviolet light curable cyan methacrylate on saline immersed in-vitro sheep heart [O] . V Garcia-Martinez, C Lopez Sanchez, W Hamed, 2016

1. Simultaneous Determination of N-Acetyl Cysteine and Taurine by HPTLC Method in Active Pharmaceutical Ingredient and Pharmaceutical Dosage Form [J] . A. R. Magesh ,Magharla Dasaratha Dhanaraju . 美国分析化学（英文） . 2017,第11期

2. Analysis of the Current Situation of Active Pharmaceutical Ingredient (API) Export in China [J] . Kong Deqiang1 ,Dong Li1 . 亚洲社会药学 . 2019,第003期

3. 内服外敷大黄提取物对188例肥胖症患者住院治疗的疗效观察 [C] . 焦东海 ,高雅萍 ,沈学敏 . 中国科协首届学术年会 . 1999

4. 富含PA大豆提取物对肥胖小鼠预防作用的初步机制研究 [A] . 廖艳林 . 2019